Threatening to upset Pfizer’s (NYSE: PFE) dominance of the multi-billion dollar coronavirus vaccine market, Moderna (Nasdaq: MRNA) is today starting legal action against the firm, claiming patent infringement.
The company has previously pledged not to enforce its patents while the pandemic continued, but as the acute phase of the health emergency recedes, Moderna is taking a more combative stance.
Since the start of the pandemic, Pfizer and co-developer BioNTech (Nasdaq: BNTX) - also a target in the litigation - have made tens of billions of dollars.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze